AstraZeneca's leading lung cancer drug, Tagrisso, accepted and granted priority review in the US 17-Oct-2023 By Liza Laws AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.